Angiogram Based Fractional Flow Reserve in Patients With Multi-Vessel Disease
1 other identifier
observational
50
1 country
1
Brief Summary
This is a prospective, observational, single-center, single-arm, clinical trial designed to assess the efficacy of FFRangio in measuring FFR obtained from angiography compared to Invasive FFR for diagnosing hemodynamically significant coronary stenosis in Multi-Vessel Disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 14, 2017
CompletedFirst Submitted
Initial submission to the registry
February 28, 2018
CompletedFirst Posted
Study publicly available on registry
March 6, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 2, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
May 2, 2018
CompletedJune 25, 2018
June 1, 2018
6 months
February 28, 2018
June 21, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Sensitivity and specificity of the dichotomously scored FFRangio measured index compared to invasive FFR
Sensitivity and specificity of the dichotomously scored FFRangio measured index per vessel as compared with invasively-derived FFR; Index ≤ 0.80 is scored "positive" while Index \> 0.8 is negative.
1 hour
Secondary Outcomes (2)
Continuously scored FFR (FFRangio and Invasive FFR).
1 hour
Accuracy, Positive predictive value and negative predictive value per vessel and per lesion
1 hour
Interventions
FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure. The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques.
Eligibility Criteria
Subjects with stable angina, unstable angina or NSTEMI who are referred to coronary angiography, have multi-vessel coronary artery disease and have an invasive FFR measurement at two lesions at minimum. Each subject will undergo both the standard invasive FFRs and the investigational FFRangio.
You may qualify if:
- \>18 years of age.
- Patients with stable angina or unstable angina or NSTEMI, with at least 1 stenoses ≥ 50% in two main vessels (LAD, LCX and/or RCA) each and in whom invasive FFR is being assessed at these stenoses.
- Patients undergoing invasive FFR with Adenosine, ATP or Papaverine used as hyperemic stimulus.
- Written, informed consent.
You may not qualify if:
- Contraindication for FFR examination or administration of vasodilators.
- Clinical presentation of an acute infarct (STEMI) or presented with STEMI in past year.
- CTO in a target vessel.
- Prior CABG, valvular surgery, TAVI/TAVR, or heart transplantation.
- Known LVEF ≤45%.
- Arteries supplying akinetic or severe hypokinetic territories if already known based on prior imaging.
- TIMI Grade 2 or lower at baseline.
- Target lesions involve Left Main (stenosis ≥50%.)
- In-stent restenosis in a target vessel.
- Heavily diffused atherosclerosis diseases defined as the presence of diffuse, serial gross luminal irregularities present in the majority of the coronary tree.
- Target coronary vessels are supplied by major collaterals.
- Lesion is in ectatic segment which includes dilatation in diameter at least 1.5 times that of the adjacent normal coronary artery.
- Coronary angiograms not acquired per instructions as defined in the Study Protocol.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- CathWorks Ltd.lead
Study Sites (1)
Gifu Heart Center
Gifu, 500-8384, Japan
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 28, 2018
First Posted
March 6, 2018
Study Start
November 14, 2017
Primary Completion
May 2, 2018
Study Completion
May 2, 2018
Last Updated
June 25, 2018
Record last verified: 2018-06
Data Sharing
- IPD Sharing
- Will not share